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Nutlin-3 preferentially sensitises wild-type
p53-expressing cancer cells to DR5-selective
TRAIL over rhTRAIL
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W J Quax5, E G E de Vries1 and S de Jong*,1
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Groningen, Groningen, The Netherlands; 2Department of Gynecologic Oncology, Cancer Research Center Groningen, University
of Groningen, University Medical Centre Groningen, Groningen, The Netherlands; 3Department of Pathology, Cancer Research
Center Groningen, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands; 4Department of
Pharmacy, Toxicology and Targeting, Groningen Research Institute for Pharmacy, University of Groningen, Groningen, The
Netherlands and 5Department of Pharmaceutical Biology, Groningen Research Institute for Pharmacy, University of Groningen,
Groningen, The Netherlands
Background: Tumour cell-selective activation of apoptosis by recombinant human TNF-related apoptosis-inducing ligand
(rhTRAIL) is enhanced through co-activation of p53 by chemotherapeutic drugs. The novel anticancer agent nutlin-3 provides a
promising alternative for p53 activation by disrupting the interaction between p53 and its negative feedback regulator MDM2.
Methods: We examined whether nutlin-3 enhances apoptosis induction by rhTRAIL and the DR5-selective TRAIL variant
D269H/E195R in wild-type p53-expressing ovarian, colon and lung cancer cell lines and in an ex vivo model of human
ovarian cancer.
Results: Nutlin-3 enhanced p53, p21, MDM2 and DR5 surface expression. Although nutlin-3 did not induce apoptosis, it
preferentially enhanced D269H/E195R-induced apoptosis over rhTRAIL. Combination treatment potentiated the cleavage of
caspases 8, 9, 3 and PARP. P53 and MDM2 siRNA experiments showed that this enhanced apoptotic effect was mediated by wild-
type p53. Indeed, nutlin-3 did not enhance rhTRAIL-induced apoptosis in OVCAR-3 cells harbouring mutant p53. Addition of the
chemotherapeutic drug cisplatin to the combination further increased p53 and DR5 levels and rhTRAIL- and D269H/E195R-
induced apoptosis. As a proof of concept, we show that the combination of D269H/E195R, nutlin-3 and cisplatin induced massive
apoptosis in ex vivo tissue slices of primary human ovarian cancers.
Conclusion: Nutlin-3 is a potent enhancer of D269H/E195R-induced apoptosis in wild-type p53-expressing cancer cells. Addition
of DNA-damaging agents such as cisplatin further enhances DR5-mediated apoptosis.
Cancer remains one of the leading causes of death in developed
countries and cancer mortality is expected to continue to rise
globally, so new drugs are urgently required. An abundance of
cancer drugs, often molecularly targeted and rationally designed,
are currently becoming available for use in the clinic. Many of the
newly developed targeted drugs will exert only modest activity
when applied alone and will be more effective when combined with
other drugs. Examination of rationalised combinations and
optimising their antitumour activity is therefore highly relevant
to improve therapy.
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An example of a drug with clear preclinical activity and modest
activity in the clinic is recombinant human TNF-related apoptosis-
inducing ligand (rhTRAIL) or Dulanermin. It can bind to pro-
apoptotic TRAIL death receptors, designated death receptor DR4
or TRAIL-R1 and DR5 or TRAIL-R2, leading to selective apoptosis
induction in tumour cells, while leaving normal cells unharmed
(Wiley et al, 1995; Pitti et al, 1996; Ashkenazi et al, 1999; Herbst
et al, 2010; Soria et al, 2011). DR-specific agonistic antibodies and
rhTRAIL variants have been generated to specifically target one
TRAIL death receptor to enhance efficacy (Ichikawa et al,
2001; Kelley et al, 2005; Pukac et al, 2005; van der Sloot et al,
2006; Adams et al, 2008; Li et al, 2008; Tur et al, 2008; Reis
et al, 2009, 2010). For example, E195R/D296H, a DR5-selective
variant of rhTRAIL, has increased affinity for DR5 and was a more
effective apoptosis inducer as compared with rhTRAIL in various
cell lines and in a bioluminescent xenograft model of ovarian
cancer (van der Sloot et al, 2006; Duiker et al, 2009). The efficacy of
rhTRAIL-induced apoptosis can be further enhanced by a rational
combination of drugs targeting complementary apoptotic path-
ways (Hougardy et al, 2005; Duiker et al, 2009; Mahalingam et al,
2009).
RhTRAIL activates the extrinsic apoptotic pathway in which
binding to DR4 and DR5 results in the formation of the death-
inducing signalling complex (DISC), comprising Fas-associated
death domain (FADD) and caspase 8 (Walczak and Sprick, 2001).
Following DISC formation, caspase 8 is cleaved, leading to either
direct activation of caspase 3 or engagement of the intrinsic
(mitochondrial) apoptotic pathway via Bid cleavage, leading to
caspase 3 activation and eventually to apoptosis. Chemotherapeutic
drugs and radiation, in general, induce the intrinsic apoptotic
pathway that involves DNA damage-induced activation of
signalling proteins including the tumour suppressor protein p53.
P53, an important transcription factor, subsequently triggers cell
cycle arrest and/or apoptosis via p53-mediated release of apoptotic
factors from the mitochondria leading to cleavage of caspases 9 and
3 (Adams and Cory, 2007; Vousden and Lane, 2007). Combination
of rhTRAIL with chemotherapeutic drugs thus results in
simultaneous activation of the extrinsic and intrinsic apoptotic
pathways, leading to strong apoptosis in tumour cells in preclinical
models (Mahalingam et al, 2009). In the clinic, data have been
reported regarding a patient with refractory chondrosarcoma who
showed a partial response to treatment with Dulanermin as a single
agent (Subbiah et al, 2012). However, phase 2 randomised studies
have not yet shown a clear advantage of the addition of rhTRAIL
or death receptor-targeting antibodies to chemotherapy (den
Hollander et al, 2013).
Therefore, an even more pronounced exploitation of the
intrinsic pathway might be relevant. In this respect, the recently
developed drug nutlin-3 is of interest. Nutlin-3 is a small molecule
that binds MDM2, which is a negative feedback regulator of p53
activity by forming a complex with p53. In addition, MDM2 in
complex with p53 can induce proteasomal degradation of p53.
Disruption of the MDM2–p53 interaction by nutlin-3 results in
accumulation of p53 in the absence of DNA damage. Nutlin-3
effectively induced p53 levels in a panel of cancer cell lines carrying
wild-type p53, resulting in apoptosis or cell cycle arrest in vitro as
well as in vivo (Ashcroft and Vousden, 1999; Vassilev et al, 2004;
Bond et al, 2005; Tovar et al, 2006). Nutlin-3 is currently in early
clinical development and might especially be of interest for the
50% of the tumours that carry wild-type p53 (Brown et al, 2009;
Levine and Oren, 2009).
In the present study, we have used nutlin-3 as a novel approach
to activate p53 and the intrinsic apoptotic pathway in a panel of
wild-type p53-expressing human cancer cell lines. Next, we
explored the effect of combining nutlin-3 and extrinsic apoptotic
pathway activation by rhTRAIL. We compared the apoptosis-
inducing ability of rhTRAIL vs the DR5-selective TRAIL variant
D269H/E195R when combined with nutlin-3. Finally, an innova-
tive living ex-patient model of primary human ovarian cancers was
included to test the functionality of TRAIL receptor-targeting
drugs and nutlin-3 in combination with cisplatin in a clinically
more relevant context.
MATERIALS AND METHODS
Reagents. RhTRAIL and D269H/E195R were produced as
described earlier (van der Sloot et al, 2006). Nutlin-3 was
purchased from Cayman Chemical (Huissen, the Netherlands)
and caspase inhibitor 1 (zVAD-FMK) from Calbiochem (via
Omnilabo, Breda, the Netherlands).
Cell culture. The human ovarian cancer cell line A2780 was
kindly provided by Dr TC Hamilton (Fox Chase Cancer Center,
Philadelphia, USA). The human H460 non-small cell lung cancer,
the human Lovo colon cancer and the human OVCAR-3 ovarian
cancer cell lines were purchased from American Type Culture
Collection. A2780, H460 and Lovo carry wild-type p53, whereas
OVCAR-3 carries mutant p53. A2780 was cultured in RPMI 1640
(Gibco, Paisley, Scotland), supplemented with 10% heat-inacti-
vated fetal calf serum (FCS) (Bodinco BV, Alkmaar, the Nether-
lands) and 0.1 M L-glutamine, H460 and Lovo in RPMI 1640,
supplemented with 10% heat-inactivated FCS, OVCAR-3 in
DMEM high glucose (Invitrogen, Breda, the Netherlands),
supplemented with 10% heat-inactivated FCS and 0.1M
L-glutamine. All cell lines grew as monolayers and were cultured
in a humidified atmosphere with 5% CO2.
Cytotoxicity assay. The microculture tetrazolium assay was used
to measure cytotoxicity. Cell lines were cultured in HAM/F12 and
DMEM medium, supplemented with 20% FCS and 0.1M
L-glutamine. Following 96 h treatment, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazoliumbromide (MTT)-solution at a concen-
tration of 5mgml 1 (Sigma-Aldrich Chemie BV, Zwijndrecht, the
Netherlands) was added and formazan production was measured
as described previously (Timmer-Bosscha et al, 1993). Cell survival
was defined as the growth of treated cells compared with untreated
cells and was determined in three experiments with each
performed in quadruplicate.
Determination of apoptosis. Cells were seeded in 96-well plates
and treated as indicated. Following treatment, apoptosis was
identified by staining nuclear chromatin with acridine orange.
Apoptosis was defined by the appearance of apoptotic bodies and/
or chromatin condensation by fluorescence microscopy and was
expressed as the percentage of apoptotic cells in a well. All
experiments were performed at least three times.
Western blot analysis. Cells were seeded in six-well plates and
treated as indicated. Following treatment, cells were harvested at
indicated time points by treatment with trypsin for 5min at 37 1C
and washed twice with cold PBS. Cells were lysed for 30min on ice
with M-PER lysis buffer (Pierce, Rockford, IL, USA) supplemented
with protease inhibitor followed by centrifugation (10min 10 000 g,
4 1C). Subsequently, protein concentrations were determined using
a Bio-Rad DC protein assay according to the manufacturers’
protocol (Bio-Rad, Veenendaal, the Netherlands) and cell lysates
were diluted to 1mg ml 1 with 2 SDS sample buffer (50mM
Tris–HCl (pH 6.8), 4% SDS, 10% glycerol, 10% 2--mercaptoetha-
nol, 0.002% bromophenol blue) and boiled for 5min. Total cell
lysates were size-fractionated on sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS–PAGE) and transferred onto
activated polyvinylidene difluoride membranes (Millipore BV,
Bedford, UK). After blocking for 1 h in Tris-buffered saline
(mM Tris–HCl, 137mM NaCl2) supplemented with 5% milk
powder (Merck, Darmstadt, Germany) and 0.05% Tween-20
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(Sigma-Aldrich), immunodetection of the protein of interest was
performed according to the manufacturer’s protocol. The following
antibodies were applied: caspase 3 (9662), cleaved caspase 3 (9661),
caspase 8 (9746), caspase 9 (9502), PUMA (4976), DR5 (3696)
(all from Cell Signaling, Leusden, the Netherlands), p53 (DO-1,
Santa Cruz, Heerhugowaard, the Netherlands), p21/waf1 (OP64),
MDM2 (Ab-1) (both from Calbiochem), noxa (ALX-804-408,
Alexis, Lausen, Switzerland), DR5 (ALX-210-743-c200, Alexis) and
PARP (11 835 238 001, Roche Diagnostics, Almere, the Nether-
lands). The Bid antibody was kindly provided by Dr J Borst (the
Netherlands Cancer Institute, Amsterdam, the Netherlands).
Binding of these antibodies was determined using horseradish
peroxidase (HRP)-conjugated secondary rabbit anti-mouse
and goat anti-rabbit antibodies (DAKO, Glostrup, Denmark).
Visualisation was performed with LumiLight Plus Western Blotting
Substrate (Roche Diagnostics). Equal protein loading was con-
firmed by immunostaining with b-actin antibody (mouse, A5441;
Sigma-Aldrich). All experiments were performed at least three
times.
Flow cytometry. Cells were seeded in six-well plates and treated as
indicated. After treatment, cells were harvested at indicated time
points by treatment with cell dissociation buffer (Gibco) for 5min
at 37 1C and washed twice with cold PBS supplemented with 2%
FCS and 0.1% sodium azide. The following antibodies were used
to determine TRAIL receptor membrane expression: TRAIL-R1
(HS101), TRAIL-R2 (HS201), TRAIL-R3 (HS301), TRAIL-R4
(HS402) (all purchased from Alexis) and phycoerythrin (PE)-
conjugated goat anti-mouse. Mouse IgG (Dako) was used as
isotype control. TRAIL receptor membrane expression was
analysed using a flow cytometer (FACSCalibur, Becton Dickinson
Biosciences, Franklin Lakes, NJ, USA) and is shown as mean
fluorescent intensity (MFI) of all analysed cells from at least three
separate experiments.
RNA interference. Small interfering RNAs (siRNAs) specific
for p53, MDM2 and Bid were designed. The double-stranded
sequences were: 50AAGACUCCAGUGGUAAUCUAC-dTdT30
(sense) and 50GUAGAUUACCACUGGAGUCUU-dTdT30 (anti-
sense) for p53, 50AAGCCAUUGCUUUUGAAGUUA-dTdT30
(sense) and 50UAACUUCAAAAGCAAUGGCUU-dTdT30 (anti-
sense) for MDM2, and 50GAAUAGAGGCAGAUUCUGA-dTdT30
(sense) and 50UCAGAAUCUGCCUCUAUUC-dTdT30 (anti-
sense) for Bid. Cells were seeded in six-well plates. The next day,
the subconfluent cells were incubated in unsupplemented Opti-
mem medium (Gibco) and transfected with 133 nM p53, MDM2,
Bid or negative control siRNA (Eurogentec, Seraing, Belgium)
using Oligofectamine reagent according to the manufacturer’s
protocol (Invitrogen). Twenty four hours after siRNA treatment,
cells were seeded for apoptosis assays or western blot analysis and
treated as indicated.
Tissue collection for ex vivo tissue slice experiments. Epithelial
ovarian cancer tissue samples were obtained from patients
undergoing primary surgery at the UMCG. All histological
subtypes were included in the study. All patients gave written
informed consent. We assessed 50 specimens for adequacy based
on tumour cell content, size of the specimen and tissue consistency,
and rejected 41 specimens based on these criteria, mostly due to
low or no tumour cell content. Finally, five specimens were used to
optimise our protocols and incubation times. Four tumour
specimens were used for combination treatments. Tumour speci-
mens obtained from ovaries or omentum were placed on ice-cold
medium (DMEM high glucose (Invitrogen) supplemented with
10% FCS, 1% penicillin/streptomycin, 2.5 mgml 1 amphotericin B
and 50 mgml 1 gentamicin) immediately following surgical
resection. Specimens were used for the experiment within a few
hours after resection.
Preparation and incubation of tissue slices. Cores of 5mm were
prepared manually from the obtained tumour specimen, embedded
in 2% agarose (Low-gelling-temperature agarose type VII, Sigma-
Aldrich) and placed in a Krumdieck Tissue Slicer (Alabama
Research and Development, Munford, AL, USA). Slicing was
performed under buffered conditions in ice-cold oxygen-saturated
Krebs–Henseleit buffer (KHB) (supplemented with 25mM glucose
(Merck), 25mM NaHCO3 (Roth, Karlsruhe, Germany), 10mM
HEPES (Roth), pH 7.4). Tissue slices of B200–300 mm thickness
and a wet weight of 10–14mg were generated using standard
settings (cycle speed setting 30; interrupted mode) and collected in
ice-cold KHB. Within 1 h after slicing, three slices were fixed in
formalin to serve as 0 h controls and the other slices were
incubated individually in six-well plates in oxygen-saturated
medium (DMEM high glucose (Invitrogen) supplemented with
10% FCS, 1% penicillin/streptomycin, 2.5mgml 1 amphotericin B
and 50 mgml 1 gentamicin). Plates were placed in plastic
containers allowing constant gassing with carbogen and incubated
at 37 1C, while gently shaking (de Graaf et al, 2010). Depending on
the number of slices that could be obtained, drug combinations
were added in triplicates as indicated after 1 h incubation.
Following 24 h treatment, slices were fixed in formalin and
paraffin-embedded. Sections (4 mm) were cut from the paraffin-
embedded slices, mounted on APES-coated slides, deparaffinised
by standard procedure and stained with hematoxylin–eosin (H&E).
Apoptosis was cytomorphologically scored based on H&E staining
as described earlier (Hougardy et al, 2008).
Immunohistochemistry. Sections were immunohistochemically
stained for cleaved caspase 3 with a polyclonal rabbit anti-cleaved
caspase 3 antibody (3661, Cell Signaling) as described previously
(Hougardy et al, 2008).
Statistical analysis. All experiments were performed indepen-
dently at least three times, except otherwise indicated. Data are
represented as the mean±s.d. Statistical analyses were performed
using two-tailed Student’s t-test. Two-tailed P-values o0.05 were
considered significant.
RESULTS
Nutlin-3 increased p53, p21, MDM2 protein levels, and DR5
surface expression. We used wild-type p53-expressing human
cancer cell lines from different tumour types to assess the effect of
nutlin-3. A2780 ovarian cancer, Lovo colon cancer and H460 non-
small cell lung cancer cells were treated for 24 h with increasing
concentrations of nutlin-3 after which p53, p21 and MDM2
protein levels were determined. Nutlin-3 dose-dependently
enhanced p53, p21 and MDM2 levels, which indicates transcrip-
tional activation of p53 due to the effective disruption of
the MDM2–p53 interaction (Figure 1A). Next, we investigated
whether nutlin-3 affected expression of DR5, a transcriptional
target of p53 (Wu et al, 1997). Indeed, DR5 protein levels were
increased upon nutlin-3 treatment in these cell lines (Figure 1A).
Moreover, DR5 membrane expression of all cell lines increased
upon treatment with increasing concentrations of nutlin-3. DR4
membrane expression remained negative in A2780 cells and stable
in H460 cells, whereas DR4 membrane expression decreased in
Lovo cells. Membrane levels of decoy receptor 2 (DcR2) did not
change, whereas decoy receptor 1 (DcR1) levels were not detected
in these cell lines (Figure 1B).
Nutlin-3 preferentially enhanced apoptosis induction by
D269H/E195R over rhTRAIL. We examined whether enhanced
p53 and DR5 expression by nutlin-3 sensitised cells to rhTRAIL
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and D269H/E195R (100 ngml 1). Nutlin-3 treatment for 24 h was
not an effective apoptosis inducer in A2780, H460 or Lovo cells.
Therefore, A2780 cells were treated for 24 h with nutlin-3, while
either rhTRAIL or D269H/E195R was added during the last 4 h of
treatment. A2780 cells were modestly sensitive to rhTRAIL and
more sensitive to D269H/E195R, showing 7±2% versus 21±5%
apoptosis (Po0.009), respectively. The sequential combination of
nutlin-3 and rhTRAIL or D269H/E195R strongly increased
apoptosis. With 20 mM nutlin-3 the increase in apoptosis in
A2780 cells was 14.1±3.6% with rhTRAIL and 35.2±6.2% with
D269H/E195R, respectively (Po0.007, rhTRAIL vs D269H/
E195R). Interestingly, rhTRAIL induced more apoptosis than
D269H/E195R in H460 cells (32±4.4% vs 13±4.4%, Po0.003)
and in Lovo cells (29.6±4.6% vs 8.1±0.9%, Po0.001). Next, H460
and Lovo cells were concomitantly exposed to nutlin-3 and
rhTRAIL or nutlin-3 and D269H/E195R for 24 h. The combination
of nutlin-3 (20 mM) with either rhTRAIL or D269H/E195R resulted
in an increase in apoptosis in H460 cells of 36.1±5.1% and
54±12.7% (P¼ 0.09), respectively, and in Lovo cells of 28.3±6.8%
and 43.8±8.3% (P¼ 0.07), respectively (Figure 2A). Summarising,
in all cell lines tested the sensitising effect of nutlin-3 on ligand-
induced apoptosis was more pronounced in combination with
D269H/E195R.
Nutlin-3 combined with rhTRAIL or D269H/E195R enhanced
caspase-dependent apoptosis. The molecular mechanism of
enhanced apoptosis induction following combination treatment
was further analysed in ovarian cancer models. Hence, the effect of
single and combined treatment regimens on apoptosis at the level
of caspases 8, 9, 3 and PARP cleavage was examined in A2780 cells.
Treatment with nutlin-3 (24 h) or rhTRAIL (4 h) did not induce
caspase or PARP cleavage. D269H/E195R (4 h) induced mild
cleavage of caspase 8, caspase 9, caspase 3 and PARP. Clearly,
cleavage of all three caspases and PARP was strongly induced upon
combined nutlin-3 and D269H/E195R treatment, and somewhat
less with the combination of nutlin-3 and rhTRAIL (Figure 2B).
Apoptosis induction by the combination was caspase-dependent,
as pre-incubation (1 h) with the broad-caspase inhibitor zVAD-
FMK (50 mM) prior to the addition of rhTRAIL or D269H/E195R
completely prevented apoptosis induction (Figure 2C).
The sensitising effect of nutlin-3 was dependent on the
disruption of the MDM2–p53 interaction. To exclude
p53-independent effects of MDM2 that have been described
(Zhang and Zhang, 2005), MDM2 was downregulated using siRNA
in A2780 cells. Effective downregulation of MDM2 resulted in
significantly higher apoptosis levels induced by D269H/E195R and
a trend for rhTRAIL (Figure 3A). Nutlin-3 less effectively
enhanced apoptosis in MDM2-suppressed cells, in line with the
MDM2 dependency of nutlin-3. For instance, treatment with 20mM
nutlin-3 caused an increase in rhTRAIL-induced apoptosis of
17.8±3.1% in control siRNA-treated A2780 cells and 2.8±2.6% in
MDM2-suppressed A2780 cells (Po0.003). A comparable effect
was observed for D269H/E195R in combination with 20 mM
nutlin-3, causing an increase in the apoptosis of 38.7±6.6% in
control siRNA-treated A2780 cells and 20.7±7.2% in MDM2-
suppressed A2780 cells (Po0.03). Next, we assessed using p53
siRNA whether the apoptosis-stimulating effect of nutlin-3 by
MDM2 blocking was due to p53 activation. Apoptosis levels
following nutlin-3 and rhTRAIL or D269H/E195R in p53-
suppressed cells were significantly lower at most nutlin-3
concentrations compared with p53-proficient cells (Figure 3B).
Using 20 mM nutlin-3, an increase in rhTRAIL-induced apoptosis
of 17.8±3.1% in control siRNA-treated A2780 cells and 8.5±3.5%
in p53-suppressed A2780 cells (Po0.025) was found. A similar
effect was found for D269H/E195R and 20 mM nutlin-3, showing an
increase in D269H/E195R-induced apoptosis of 36.1±4.2% in
control siRNA-treated A2780 cells and 16.7±2.6% in p53-
suppressed A2780 cells (Po0.005), confirming p53 dependency
of the nutlin-3 effect. Upon treatment with nutlin-3, OVCAR-3
cells carrying mutant p53 were not sensitised to rhTRAIL or
D269H/E195R, while pre-treatment with cisplatin increased the
apoptotic effect of both ligands (Supplementary Figure 1A and B).
Together, these results indicate that disruption of the MDM2–p53
interaction by nutlin-3 leading to p53 activation is the main
mechanism underlying sensitisation for rhTRAIL and D269H/
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Figure 1. Nutlin-3 treatment induced upregulation of p53, p21, MDM2 and DR5 (membrane) expression. (A) Treatment of A2780, H460 and Lovo
with increasing concentrations of nutlin-3 for 24 h resulted in a dose-dependent upregulation of p53, MDM2, p21 and DR5 protein levels as
determined by western blotting. (B) DR4, DR5 and DcR2 membrane expression levels were measured using FACS analysis demonstrating that
nutlin-3 enhanced DR5 levels dose-dependently, whereas DcR2 remained unchanged. In H460 and Lovo, DR4 levels decreased upon treatment.
DcR1 was not detected. Presented data are representative for at least three independent experiments and mean MFI levels are shown ±s.d.
*Po0.05, **Po0.01 compared with DR5 MFI at 0mM nutlin-3. #Po0.05 compared with DcR2 MFI at 0 mM nutlin-3.










































































Nutlin-3 + ZVAD (50 M)
rhTRAIL (100 ng ml–1)
D269H/E195R (100 ng ml–1)
Caspase 8
– – – –+ +
– – + +– –




Treatment (100 ng ml–1)
-actin
Cleaved caspase 3
Cleaved caspase 8 (p18)
0 5 10 20
Nutlin-3 (M)
0 5 10 20
Nutlin-3 (M)
0 5 10 20
Figure 2. Nutlin-3 enhanced apoptosis induction by rhTRAIL and especially D269H/E195R. (A) Pre-treatment of A2780 cells for 20 h with
increasing concentrations of nutlin-3 followed by addition of rhTRAIL or D269H/E195R for 4 h dose-dependently increased the percentage of
apoptotic cells in particular when using D269H/E195R. Combined treatment for 24 h dose-dependently sensitised H460 and Lovo to rhTRAIL and
D269H/E195R-induced apoptosis. Apoptosis was determined using an acridine orange assay. *Po0.05, **Po0.01 compared with 0mM nutlin-3.
(B) Combination treatment with nutlin-3 (24 h) and rhTRAIL or D269H/E195R (4 h) resulted in caspase activation and PARP cleavage, with strongest
activation following nutlin-3 and D269H/E195R. (C) Apoptosis induction by the combination was completely blocked by 1h pre-treatment with
ZVAD-FMK (50mM). *Po0.01 compared with 0 mM nutlin, #Po0.01 compared with 0mM nutlin-3 and 20mM nutlin-3. Presented data are
representative for at least three independent experiments.
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Figure 3. The sensitising effect of nutlin-3 on rhTRAIL- or D269H/E195R-induced apoptosis was exerted via a specific block of the MDM2–p53
interaction. A2780 cells were transfected with MDM2- or p53-specific siRNAs and 48h after transfection, cells were treated with the nutlin-3 and
rhTRAIL or D269H/E195R combinations. Apoptosis induction was determined by acridine orange. (A) MDM2 was effectively silenced (right panel)
and caused sensitisation of cells to rhTRAIL and D269H/E195R, while the sensitising effect of nutlin-3 was abrogated (left panel). (B) P53 was
effectively silenced (right panel) and decreased the sensitising effect of nutlin-3 at different concentrations (left panel). #Po0.05, ##Po0.01
compared with nutlin-3-treated negative control siRNA. Presented data are representative for at least three independent experiments.
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E195R. Moreover, the sensitising effect of cisplatin appears to
involve a p53-independent mechanism.
Nutlin-3 in combination with rhTRAIL or D269H/E195R
activated apoptosis via Bid. In order to investigate whether
nutlin-3 activated the intrinsic apoptotic pathway, we examined
the effect of nutlin-3 on protein levels of PUMA and Noxa, known
to be regulated by p53. PUMA levels were not affected by nutlin-3
and Noxa levels even decreased in A2780 (Figure 4A). Next, Bid
was silenced with selective siRNA to block caspase 8-mediated
activation of the intrinsic apoptosis pathway following rhTRAIL
treatment. Efficient downregulation of Bid (Figure 4C) almost
completely prevented apoptosis induction by the combination of
rhTRAIL or D269H/E195R with nutlin-3 (Figure 4B). This is
illustrated by the lowered rhTRAIL and D269H/E195R-induced
apoptosis levels in Bid-suppressed A2780 cells compared with
control siRNA-treated A2780 cells pretreated with 20 mM nutlin-3
(11.3±4.5% vs 51.3±1.5%, Po0.0001 for rhTRAIL; 36±11.4%
vs67.3±11.7%, Po0.029 for D269H/E195R). The reduction in
apoptosis in Bid siRNA-treated cells compared with negative
control siRNA-treated cells was reflected in the strong reduction in
cleavage of caspases 9 and 3. Cleavage of caspase 8, however, was
hardly affected by Bid downregulation, indicating that caspase 8
activation was not due to a functional feedback of caspase 3/9
(Figure 4C). Together, our data show that nutlin-3 sensitises A2780
cells to rhTRAIL and D269H/E195R by enhanced caspase 8
activation, which facilitates truncated Bid-dependent activation of
the intrinsic apoptotic pathway that is essential for apoptosis in
these cells.
Cisplatin augmented nutlin-3-induced p53 activation and
DR5-mediated apoptosis. Platinum-based chemotherapy is the
standard of care for ovarian cancer. Therefore, we examined
whether cisplatin could further enhance the effect of nutlin-3 in
combination with rhTRAIL and D269H/E195R. A2780 cells were
pretreated for 4 h with cisplatin, washed and further incubated for
16 h with nutlin-3 to allow maximal p53 induction following
cisplatin-induced DNA damage. In A2780, 1 mM of cisplatin was
sufficient to induce p53, rendering cells more susceptible to nutlin-
3 treatment, as demonstrated by a stronger induction of p53, p21
and MDM2 compared with single treatment with nutlin-3 or
cisplatin (Figure 5A). Notably, although p53 induction is far more
pronounced following cisplatin as opposed to nutlin-3 treatment,
the level of p21 and MDM2 induction is similar.
Low concentrations of cisplatin (0.1–2.5 mM) combined with
nutlin-3 (10 mM) additively increased DR5 membrane expression
levels as compared with single-agent-induced levels, whereas DcR2
levels remained unchanged (Figure 5B). Next, we examined
whether cisplatin enhanced the apoptotic effect of nutlin-3 and
rhTRAIL or D269H/E195R. Sequential treatment with cisplatin
and nutlin-3, as described before, did not induce apoptosis,
whereas nutlin-3 enhanced apoptosis induction by D269H/E195R
and rhTRAIL (4 h). A low dose of cisplatin (1 mM) sensitised A2780
to D269H/E195R but not to rhTRAIL. Triple combination of
nutlin-3 and cisplatin with D269H/E195R was more potent than
D269H/E195R combined with nutlin-3 or cisplatin (Figure 5C).
A higher dose of cisplatin (10 mM) was required to sensitise
cells to rhTRAIL and the triple combination with rhTRAIL then
showed additively enhanced apoptosis levels (Supplementary
Figure 2A).
Cell survival was also measured following 96 h combined
treatment. Our results indicate that nutlin-3 inhibited cell survival.
Moreover, nutlin-3 significantly potentiated cell survival inhibition
by D269H/E195R and rhTRAIL (Figure 5D upper panel and
Supplementary Figure 2B). Combining a low concentration of
nutlin-3 with a low concentration of cisplatin further reduced cell
survival (Supplementary Figure 2B). A significantly stronger
decrease in cell survival was observed upon combined cisplatin,
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Figure 4. Nutlin-3 in combination with rhTRAIL or D269H/E195R activated apoptosis via Bid. (A) Treatment of cells for 24 h with increasing
concentrations of nutlin-3 hardly affected PUMA expression and caused a decrease in Noxa protein levels. (B) Silencing of Bid by siRNA
completely attenuated the sensitising effect of nutlin-3 on rhTRAIL-induced apoptosis (left panel). Nutlin-3-dependent sensitisation for
D269H/E195R was not completely blocked under these conditions (right panel). #Po0.05, ##Po0.01 compared with nutlin-3-treated negative
control siRNA. (C) Bid downregulation inhibited caspase 3 and caspase 9 cleavage as induced by combined treatments. Cleavage of caspase
8 was not affected. Presented data are representative for at least three independent experiments.
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cisplatin and D269H/E195R or nutlin-3 and D269H/E195R
(Figure 5D lower panel, Supplementary Figure 2B).
We tested the possible apoptotic effects of the triple combina-
tion on the normal colon epithelial cell line NCM460. No
significant activation of apoptosis was observed following 24-h
treatment with all three drugs, indicating tumour cell-selective
activity of the triple combination without harming normal cells
(Supplementary Figure 3).
Combining nutlin-3, cisplatin and D269H/E195R massively
induced apoptosis in an innovative living ex-patient model of
primary human ovarian cancers. Finally, we evaluated whether
our treatment modalities were effective in inducing apoptosis in
primary ovarian tumour tissue cultured as ex vivo tissue slices.
Apoptosis scoring based on H&E staining showed excellent cell
viability in controls following 24 h up to 72 h of culturing.
Depending on the size of the specimen, variable numbers of slices
were generated using the Krumdieck tissue slicer and treated for
24 h with treatment regimens as indicated. In a pilot experiment,
D269H/E195R treatment induced more apoptosis compared with
rhTRAIL (data not shown). Therefore, in the subsequent
experiments, slices were treated with D269H/E195R, not with
rhTRAIL. The tumour types of the tissue samples were as follows:
clear cell ovarian cancer (different components, counted clear cell
component, patient A) and serous ovarian cancer (patient B–D).
Single treatment with cisplatin resulted in a significant induction of
apoptosis in 4/4 tumours, with D269H/E195R in 2/4 tumours and
with nutlin-3 in none of the tumours (Figure 6A). Combination
treatment of D269H/E195R and nutlin-3 resulted in significantly
higher apoptosis levels compared with D269H/E195R or nutlin-3
treatment alone in 4/4 tumours. No significant effect was observed
when nutlin-3 was added to cisplatin in 3/3 tumours. Upon
combination of all three drugs, massive apoptosis induction
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Figure 5. Cisplatin augmented nutlin-3-induced p53 activation and DR5-mediated apoptosis. A2780 cells were pretreated for 4 h with low doses
of cisplatin and after removal of cisplatin treated with nutlin-3 overnight. (A) P53, p21 and MDM2 levels were examined using western blotting.
This showed that cisplatin (10mM) combined with nutlin-3 (10mM) induces a massive upregulation of these proteins. (B) DR5 and DcR2 membrane
expression levels were determined by FACS analysis and showed that low doses of cisplatin combined with nutlin-3 (10mM) enhanced DR5 levels
when compared with nutlin-3 alone. DcR2 levels, however, remained unchanged. *Po0.05, **Po0.01 compared with DR5 MFI at 0 mM cisplatin.
#Po0.05 compared with DR5 MFI in the absence of nutlin-3. (C) rhTRAIL or D269H/E195R was added for 4 h following treatment with cisplatin
(1mM) and nutlin-3 (10mM), and apoptosis levels were examined with acridine orange. At this low dose, cisplatin additively sensitised A2780 cells to
combined nutlin-3 and D269H/E195R exposure. *Po0.05, **Po0.01 compared with untreated control. #Po0.05 apoptosis of combination
compared with the effect of each single drug from the combination. $Po0.05 triple combination compared with all other treatments. (D) Cell
survival was measured using an MTT assay following 92h continuous treatment. Treatment in the absence of rhTRAIL or D269H/E195R is set at
100%. Nutlin-3 in combination with D269H/E195R more potently inhibited cell survival compared with the combination with rhTRAIL (upper
panel). Addition of cisplatin (0.25mM) to the combination of nutlin-3 (1 mM) and D269H/E195R had a stronger effect on cell survival (lower panel).
#Po0.05, ##Po0.01 combination compared with single rhTRAIL or D269H/E195R treatment. $Po0.05 triple combination compared with D269H/
E195R plus cisplatin and with D269H/E195R plus nutlin-3 (1 mM) treatment. Presented data are representative for at least three independent
experiments.
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than the effect of each drug alone in 3/4 tumours (Figure 6A).
Next, we stained serial slides with H&E and for active caspase 3
(Figure 6B and C). Active caspase 3 levels correlated with the
observed apoptosis levels based on H&E staining as demonstrated
by strong positive staining upon combination of drugs. In the triple
combination active caspase 3 staining was less prominent, which is
probably related to the late apoptotic stage of cells as reflected by
the highly condensed nuclei in the H&E staining.
100 Patient A

















































































































































DR5 DR5+Cis DR5+N DR5+N+Cis
N N+CisCis
Un




























Figure 6. Combination of nutlin-3, cisplatin and D269H/E195R massively induced apoptosis in an ex vivo tissue slice model of primary human
ovarian cancer. Tissue slices from primary human ovarian cancer tissue were treated with the indicated combinations for 24 h. (A) Quantification
of apoptosis levels based on H&E scoring of each separate experiment. Tumour types: clear cell ovarian cancer (different components,
counted clear cell component, patient A), and serous ovarian cancer (patient B, C and D). Single drug treatment induced moderate levels of
apoptosis, which were enhanced substantially upon combination treatment. Combination of cisplatin, nutlin-3 and D269H/E195R further
enhanced apoptosis with apoptosis in over 80% of cells. *Po0.05, **Po0.01 compared with control (no drugs). #Po0.05 compared with effect of
each single drug used in the combination. (B) H&E staining of a representative experiment showed excellent cell viability following 24h incubation.
Increased numbers of apoptotic cells can be seen following treatment with cisplatin (10mM), nutlin-3 (20mM), or D269H/E195R (0.25mg ml1).
Combined treatment further enhanced number of apoptotic cells and combination of all three drugs showed massive apoptosis induction with
almost no viable cells left. (C) Representative active caspase 3 staining corresponding with the H&E slides. The levels of active caspase 3 nicely
correlate with the quantified number of apoptotic cells based on the H&E stainings. (Un), no drugs added; (Cis), cisplatin; (N), nutlin-3;
(DR5), D269H/E195R. Bars indicate 50mm.
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DISCUSSION
In the present paper, we showed that the MDM2-blocking agent
nutlin-3 acts as an enhancer of TRAIL receptor-induced apoptosis
in a p53-dependent manner. Moreover, the combination of nutlin-
3 with the DR5-selective TRAIL variant D269H/E195R was
substantially more effective in inducing apoptosis than nutlin-3
combined with rhTRAIL. This was related to the nutlin-3-
dependent increase in DR5 expression. Adding cisplatin to the
combination further enhanced apoptosis induction. Interestingly,
nutlin-3 and D269H/E195R mildly induced caspase 3 cleavage and
apoptosis as single agents in a novel living ex-patient model of
primary human ovarian cancers. Combination of nutlin-3 and
D269H/E195R induced more apoptosis and caspase 3 cleavage in
these tumour tissue slices. Cisplatin was effective as single agent
but even more effective in the triple combination treatment, which
induced massive apoptosis in the tumour slices. As platinum-based
chemotherapy is the cornerstone of ovarian cancer treatment,
this illustrates the potential clinical relevance of our findings.
Approximately half of all human tumours express wild type p53,
but these tumours often display a hampered p53 function, due to
enhanced levels of MDM2 in complex with p53 (Vassilev, 2007).
Via disruption of the MDM2–p53 complex, nutlin-3 effectively
induced p53 levels in a panel of cancer cell lines carrying wild-type
p53, resulting in apoptosis or cell cycle arrest in vitro as well as
in vivo (Vassilev et al, 2004; Tovar et al, 2006; Koster et al, 2011).
Nutlin-3 hardly induced apoptosis in our panel of wild-type p53
cell lines, which has been observed by others as well in a subgroup
of cell lines (Tovar et al, 2006). This may be related to downstream
defects in the p53-dependent intrinsic apoptosis pathway
(Hougardy et al, 2005). We and others found that nutlin-3
increases promoter activity and membrane expression of DR5
(Secchiero et al, 2007; Hori et al, 2010). Nutlin-3 had no effect on
DR4 or even decreased DR4 membrane expression in our panel of
ovarian, lung and colon cell lines. Therefore, we explored the
attractive strategy to combine nutlin-3 with drugs that induce
apoptosis via the DR5-mediated extrinsic pathway, such as
rhTRAIL (Secchiero et al, 2007; Hori et al, 2010). To fully exploit
the effect of nutlin-3 on DR5, we used a DR5-selective TRAIL
variant with mutations D296H and E195R (van der Sloot et al,
2006; Duiker et al, 2009). Indeed, nutlin-3 preferentially poten-
tiated the effect of D269H/E195R over rhTRAIL not only in
ovarian cancer cells but also in lung and colon cancer cells.
Importantly, normal colon epithelial cells were not affected by the
combination. D269H/E195R has a higher affinity for DR5 as
compared with rhTRAIL, which may explain the increased efficacy
of the combination with nutlin-3 (Szegezdi et al, 2012). This is
supported by our finding that D269H/E195R in combination with
nutlin-3 more potently activated caspase 8- and caspase 9-induced
caspase 3 cleavage.
DR5-specific targeting is an interesting antitumour strategy, as
combinations of various drugs such as proteasome inhibitors or
cisplatin with rhTRAIL more often upregulated DR5 than DR4
(Pennarun et al, 2010). In addition, high DR5 expression measured
immunohistochemically in tumours of ovarian cancers patients
correlated with poor patient survival and DR5 was upregulated
following chemotherapy (Arts et al, 2004; Ouellet et al, 2007).
Previously, we showed that cisplatin caused increased levels of p53
and DR5 membrane expression and enhanced rhTRAIL-induced
apoptosis in ovarian cancer cell lines (Duiker et al, 2009; Duiker
et al, 2011). Moreover, enhanced in vivo efficacy of D269H/E195R
over rhTRAIL in combination with cisplatin was shown with an
orthotopic A2780 bioluminescent xenograft model (Duiker et al,
2009). However, tumour growth resumed upon discontinuation
of combined treatment. Thus, more potent combinations
are warranted. Interestingly, cisplatin-induced p53 expression
was not required for DR5 upregulation and rhTRAIL-sensitisation
in A2780 cells (Duiker et al, 2011), in contrast to nutlin-3-induced
p53 expression as shown in the present study. Nutlin-3 is known to
enhance p53 levels without genotoxic effects (Vassilev, 2007).
In order to benefit from the putative difference in p53 activation
via cisplatin-induced DNA damage and nutlin-3, we included
nutlin-3 in the ovarian cancer cell models. Accumulation of
unphosphorylated p53 functions equally well as a transcription
factor compared with DNA damage-induced phosphorylated p53
(Thompson et al, 2004), which was reflected in the nutlin-3-
induced DR5 upregulation. Upon combination of cisplatin and
nutlin-3, massive p53 induction occurred, resulting in strong
upregulation of p21, MDM2 and DR5. As a consequence, nutlin-3
rendered cells more susceptible to D269H/E195R as well as to
D269H/E195R combined with cisplatin.
The in vitro results were translated into an innovative living
ex vivo patient model of ovarian cancer. This model might be
physiologically more relevant over in vitro cell line models and
primary tumour cell cultures, as it takes tumour–stroma interac-
tions into account. Moreover, heterogeneity of individual tumours
and between the tumours can be evaluated. In concordance with
our in vitro data, D269H/E195R was more potent than rhTRAIL as
a single agent. Sensitivity to D269H/E195R was observed in two of
the four tumours. An analogous observation was made with the
anti-DR5 antibody TRA-8 that effectively induced apoptosis in
most tumours tested using a similar ex vivo model of ovarian
cancer (Estes et al, 2007; Frederick et al, 2009). Several in vitro
studies have reported that ovarian cancer cell lines are intrinsically
resistant to rhTRAIL (for review, refer to the study by Khaider
et al, 2012). FLIP is an important candidate among others, causing
rhTRAIL resistance in ovarian cancer cells, but other resistance
mechanisms acting at the level of the DISC or more downstream
on the apoptosis pathway have been identified (Duiker et al, 2011;
Li et al, 2011; for reviews, refer to the studies by Mahalingam et al,
2009 and Pennarun et al, 2010). FLIP, caspase 8 and DR5
expression have been detected in the majority of ovarian cancer
(Arts et al, 2004; Ouellet et al, 2007; Duiker et al, 2010; El-Gazzar
et al, 2010). We and others found that many ex vivo ovarian
tumours were sensitive to DR5-targeted drugs in contrast to the
ovarian cancer cell line models, suggesting that FLIP expression is
not the only determinant of resistance (Estes et al, 2007; Frederick;
et al, 2009; Li et al, 2011). A recent study has shown that cisplatin
augments the efficacy of the anti-DR5 antibody TRA-8 in the
ex vivo model of ovarian cancer (Frederick et al, 2009). In the
present study we found that combining D269H/E195R with nutlin-
3 sensitised all ex vivo ovarian tumours, resulting in higher
apoptosis levels. Adding cisplatin to this combination further
enhanced apoptosis. This is in line with our in vitro data, indicating
that nutlin-3 and cisplatin additively enhanced D269H/E195R-
induced apoptosis via different mechanisms. However, it still
remains to be determined what the key factors in the in vivo
resistance to DR5-targeted drugs are and whether the triple
combination will overcome all potential mechanisms of resistance
in ovarian cancer.
In contrast to our previous and present in vitro data showing
that cisplatin did not induce apoptosis in the A2780 cell line model
(Duiker et al, 2009; Duiker et al, 2011), cisplatin treatment of the
ex vivo ovarian cancer patient slices caused high levels of apoptosis
in all four patient tumours. Although nutlin-3 treatment had no
additional effect on cisplatin-induced apoptosis in tumour slices or
A2780 cells, we clearly observed a stronger effect on A2780 cell
survival with this combination after 4 days (Supplementary
Figure 2B). Therefore, we may have underestimated the effect of
cisplatin and nutlin-3 using these short-term apoptosis assays.
Nutlin-3 and other MDM2 blockers are currently under clinical
investigation in haematological malignancies and solid tumours
(Brown et al, 2009). In wild-type p53-expressing tumour types
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such as testicular germ cell cancer, neuroblastoma and leukaemia,
the additively enhanced apoptotic effects of this combination were
demonstrated in in vitro models (Kojima et al, 2005; Barbieri et al,
2006; Vassilev, 2007; Bauer et al, 2010; Koster et al, 2011).
Interestingly, nutlin-3 also enhanced chemotherapy-induced
apoptosis in mutant p53-expressing cancer cells of various origins
via activation of E2F1, thus extending the applicability of cisplatin
and nutlin-3 to both wild type and mutant p53 cancer cells
(Ambrosini et al, 2007). Further investigations are required to
define the applicability of cisplatin and MDM2 inhibitor
combinations for (ovarian) cancer treatment.
In conclusion, nutlin-3 is a potent enhancer of rhTRAIL- and
especially D269H/E195R-induced apoptosis in wild-type p53-
expressing cancer cells. Adding DNA-damaging agents such as
cisplatin to the combination further enhances DR5-mediated
apoptosis. Therefore, this combination could provide an effective
treatment for (sub)groups of ovarian, colon and lung cancer
expressing wild-type p53.
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